Intellectual Property Intellectual Property All patents are owned by Adenovir Pharma. Patents have been granted in Europe, USA, Japan, China, Hong Kong and Singapore. The initial patent relates to a method and a composition for the treatment of adenoviral ocular infections. 1st patent “Method and compositions for the treatment of adenoviral ocular infections” SG 89005 CN ZL00816173.9 HK 1052139 US 7,528,113 EP-DE DE60020729.3 EP-GB 1 231 925 JP 4559613 Based on the candidate drug, APD-209, a new patent application covering substance, indication and method, has been filed internationally, as well as in Argentina and Taiwan. 2nd patent – “Antiviral compounds” WO 2011/003876   TW 201105335   AR 077391